6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16 of the

Securities Exchange Act of 1934

For the month of February 2023

Commission file number: 001-32749

FRESENIUS MEDICAL CARE AG & Co. KGaA

(Translation of registrant's name into English)

Else-Kröner Strasse 1

61346 Bad Homburg

Germany

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  x                     Form 40-F  ¨ 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

EXHIBITS

The following exhibits are being furnished with this Report:

Exhibit 99.1 Press Release issued on February 23, 2023.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

DATE: February 23, 2023

Fresenius Medical Care AG & Co. KGaA,

a partnership limited by shares, represented by:

fresenius medical care management ag, its General Partner

By:	/s/ Helen Giza
Name:	Helen Giza
Title:	Chief Executive Officer, Chair of the Management Board of the General Partner and Acting Chief Financial Officer

By:	/s/ Dr. Katarzyna Mazur-HofsÄß
Name:	Dr. Katarzyna Mazur-Hofsäß
Title:	CEO Care Enablement and member of the Management Board of the General Partner

EX-99.1

Exhibit 99.1

 

Press Release	Media Contact
	Martin Kunze
	T +49 6172 608-2115
	martin.kunze@fresenius.com
	Contact for analysts and investors
	Dr. Dominik Heger
	T +49 6172 609-2601
	dominik.heger@fmc-ag.com
	www.freseniusmedicalcare.com

February 23, 2023

Fresenius Medical Care published form 20-F for the fiscal year 2022

Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, has filed the annual report 2022 on form 20-F with the U.S. Securities and Exchange Commission (SEC). The report is available at the company’s website (freseniusmedicalcare.com) in the “Investors” section as well as at the SEC's website (www.sec.gov).

A hard copy of Fresenius Medical Care’s annual report on form 20-F including the complete audited consolidated financial statements may be obtained from the Company free of charge upon request to the company’s Investor Relations department by email at ir@fmc-ag.com.

The company also published a Facts & Figures 2022 website at www.factsandfigures.freseniusmedicalcare.com to provide an overview of the key financial figures for the fiscal year 2022. In addition, the new corporate magazine, the company profile and a five-year summary are available for download on the company website.

Fresenius Medical Care is the world’s leading provider of products and services for individuals with renal diseases of which around 3.9 million patients worldwide regularly undergo dialysis treatment. Through its network of 4,116 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approximately 345,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with its core business, the Renal Care Continuum, the company focuses on expanding in complementary areas and in the field of critical care. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

Page 1/2

For more information visit the company’s website at www.freseniusmedicalcare.com.

Disclaimer:

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to COVID-19, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA’s reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

Page 2/2